NCT02941731View on ClinicalTrials.gov

Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy
Interventions
DRUG

HIP1403

Oseltamivir 6mg/mL

DRUG

HGP0919

Oseltamivir phosphate 6mg/mL

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02941731 - Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions | Biotech Hunter | Biotech Hunter